Survey checks if doctors know epilepsy drug risks
NCT ID NCT06714448
Summary
This study aims to understand how well healthcare professionals in Saudi Arabia know and follow safety guidelines for the epilepsy medication Depakine (sodium valproate). Researchers will survey 3,500 doctors, pharmacists, and specialists who prescribe or dispense this medication. No treatments are given; this is purely an information-gathering study to improve patient safety.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EPILEPSY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sanofi-Aventis
Chilly-Mazarin, 91380, France
Conditions
Explore the condition pages connected to this study.